



# **Trojan Global Equity Fund**

All data as at 31 August 2020

www.taml.co.uk

The investment objective of the Trojan Global Equity Fund is to seek to achieve capital growth over the long term (at least 5 years). The Fund must invest globally with at least 80% of its assets in equities and equity-related securities.

Prices 423.56p


'O' Accumulation Shares

349.50p

'O' Income Shares

Fund Size £358m





Total Return to 31 August 2020	06/03/06 Since launch					29/02/20 6 months
Trojan Global Equity Fund O Acc	+323.6%	+243.5%	+104.9%	+42.4%	+7.5%	+14.7%
IA Global (TR)	+187.8%	+176.8%	+78.6%	+24.5%	+6.8%	+11.3%
MSCI World Index NR (£)	+229.3%	+218.4%	+88.6%	+27.4%	+6.2%	+10.4%

Discrete Calendar Annual Returns	2006#	2007	2008	2009	2010	2011	2012	2013
Trojan Global Equity Fund O Acc	+20.2%	-4.6%	-11.3%	+18.4%	+14.9%	+6.2%	+3.7%	+14.4%
# from launch 06/03/06		2014	2015	2016	2017	2018	2019	2020 YTD
		+15.0%	+12.3%	+19.2%	+13.2%	+1.1%	+24.6%	+10.5%

The Fund was originally launched as the Trojan Capital Fund, which focused on investing in UK equities with the flexibility to invest in overseas equities and other asset classes. The strategy was changed to a global equity strategy in December 2013. The Fund has been a constituent of the IA Global sector since April 2012. Prior to this, the Fund was in the IA Flexible Investment sector. Source: Lipper

Past performance is not a guide to future performance.

## **August Commentary**

Your Fund returned +3.5% during the month compared to +4.6% for the MSCI World Index NR (f).

Monthly returns were once again driven by the Fund's large investments across the internet, software and payments sectors. We have written extensively this year as to why we remain optimistic about these parts of the portfolio. We are equally committed to the Fund's long-term investments in companies for which the pandemic has been less positive. One such example is Medtronic, the medical device manufacturer. The company reported quarterly earnings in August and the


results revealed severe declines in revenues, profits and cashflows as deferred surgical procedures disrupted Medtronic's sales. Beneath the surface, however, are encouraging signs of progress. Medtronic's markets are recovering faster than many anticipated and the company is making moves to its competitive Medtronic reported gains in market share for several of its largest businesses, driven by new product launches. There is more to come over the next few years as the company commercialises a rich pipeline of new devices. As the inventor of the world's first wearable pacemaker in the 1950s,

Medtronic has a proud heritage in biomedical engineering. Under new CEO Geoff Martha, the company is being reorganised to sharpen its commercial execution. Mr Martha summed it up as follows: 'We're playing offense and we're energised to use this moment when our pipeline is kicking in to expand our markets and take share. And importantly, we're driving towards faster and broader top-line growth, not just from the pandemic, but sustainable growth over the long term'. Given this brightening outlook, we see the Fund's investment in Medtronic as an important source of strength, diversity and value for the portfolio.

# **Trojan Global Equity Fund**

All data as at 31 August 2020

www.taml.co.uk



Source: Lipper

Risk analysis since launch (06/03/06)	Fund	IA Global TR	Index*
Total Return	+323.6%	+187.8%	+229.3%
Max Drawdown <sup>1</sup>	-33.3%	-38.3%	-38.3%
Best Month	+9.4%	+9.8%	+10.1%
Worst Month	-9.4%	-12.9%	-10.6%
Positive Months	+62.4%	+63.0%	+63.6%
Annualised Volatility <sup>2</sup>	+11.5%	+13.7%	+13.5%

<sup>1.</sup> Measures the worst investment period \*MSCI World Index NR (£) <sup>2</sup>Measured by standard deviation of annual returns

Top 10 holdings	% Fund
Microsoft	8.0
PayPal	7.5
Alphabet	6.5
Facebook	5.7
Visa	5.3
Medtronic	5.3
American Express	4.2
Roche Holding	4.2
Novartis	4.1
Experian	3.6
Total Top 10	54.3
17 other holdings	40.2
Cash & Equivalent	5.5
TOTAL	100.0

Source: Factset. Holdings subject to change

#### **Fund information**

A copy of the latest Prospectus and the KIID for each class (in English) upon which you should base your investment decision is available from Link Fund Solutions Ltd, the Fund's Authorised Corporate Director and Link Fund Administrators Ltd (Authorised and Regulated by the Financial Conduct Authority) on 0345 608 0950.

#### tructure

Sub-fund of Trojan Investment Funds UCITS

#### Investment Manager

Troy Asset Management Limited 33 Davies Street London W1K 4BP Tel: 020 7499 4030 Fax: 020 7491 2445

email: busdev@taml.co.uk

Fund Manager Gabrielle Boyle
Assistant Fund Manager George Viney

Currency £ Sterling

Launch Date 6 March 2006

#### **Benchmarks**

For more information on the benchmarks used please refer to the 'use of benchmarks' section in the fund information sheet, available from our <u>website</u>

Ongoing Charges	
'O' (ordinary) shares:	0.92%
'S' (charity) shares:	0.82%

### Dividend Ex Dates

1 August (interim), 1 February (final)

## Dividend Pay Dates

30 September (interim), 31 March (final)

Fund Yield (historic 'O' Inc shares) 0.24%

#### **Authorised Corporate Director**

Link Fund Solutions Limited Tel: 0345 300 2110

#### ISINs

GB00B0ZJ0230 (O Inc), GB00B0ZJ5S47 (O Acc) GB00B0ZJQY73 (S Inc), GB00B0ZJSN09 (S Acc)

#### Dealing

Daily at noon Tel: 0345 608 0950

#### Registra

Link Fund Administrators Limited

#### Auditor

Ernst & Young LLP

# Depositary

The Bank of New York Mellon (International) Limited

# Bloomberg

TRJCAPA\_LN (O Acc), TRJCAPI\_LN (O Inc)

#### SEDOL

B0ZJ5S4 (O Acc), B0ZJ023 (O Inc)

#### Pricing

"O" share class prices published daily in the FT

#### Important Information

Fund performance data provided is calculated net of fees unless stated otherwise. Past performance is not a guide to future performance. All references to benchmarks are for comparative purposes only. Overseas investments may be affected by movements in currency exchange rates. The value of an investment and any income from it may fall as well as rise and investors may get back less than they invested. The historic yield reflects distributions declared over the past twelve months as a percentage of the fund's price, as at the date to not include any preliminary charge and investors may be subject to tax on their distributions. The yield is not guaranteed and will fluctuate. Neither the views nor the information contained within this document constitute investment or provide discretionary investment management services and should not be used as the basis of any investment decision. Any decision to investshould be based on information contained in the prospectus, the relevant key investor information document and the latest report and accounts. The investment policy and process of the fund(s) may not be suitable for all investors. If you are in any doubt about whether the fund(s) is/are suitable for you, please contact a professional advisor. References to specific securities are included for the opinions expressed are expressed at the date of this document to buy or sell these securities. Although Troy Asset Management Limited considers the information included in this document to be reliable, no warranty is given as to its accuracy or completeness. The opinions expressed are expressed at the date of this document and, whilst the opinions stated are honestly held, they are not guarantees and should not be relied upon and may be subject to change without notice. Third party data is provided without warranty or liability and may belong to a third party. The fund(s) is/are registered for distribution to the public in the UK and Ireland but not in any other jurisdiction. The distribution of shares of sub-funds of Tr